In a study of ROS1 fusion-positive NSCLC resistant to ROS1 inhibitors, transformation to SCLC was observed with concurrent RB1 and TP53 inactivation and loss of ROS1 fusion expression, suggesting convergent mechanisms of lineage plasticity and drug resistance [71]. This evidence concerns the gene RB1 and small cell lung carcinoma.